Drugs / Vx-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01935154 | Aug 2012 → Jan 2017 | non-small cell lung carcinoma | Vaxon Biotech | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vx-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01935154 ↗ |
| Modality | Vaccine | “The cancer vaccine Vx-001” PMID 32210365 ↗ Mar 2020 |
| Target | TERT | “The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT)” PMID 32210365 ↗ Mar 2020 |